LRIG1 Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, E |
---|---|
Primary Accession | Q96JA1 |
Other Accession | P70193, NP_056356.2 |
Reactivity | Mouse |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 119113 Da |
Antigen Region | 801-829 aa |
Gene ID | 26018 |
---|---|
Other Names | Leucine-rich repeats and immunoglobulin-like domains protein 1, LIG-1, LRIG1, LIG1 |
Target/Specificity | This LRIG1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 801-829 amino acids from the C-terminal region of human LRIG1. |
Dilution | WB~~1:1000 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | LRIG1 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | LRIG1 {ECO:0000303|PubMed:15282549} |
---|---|
Synonyms | LIG1 |
Function | Acts as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation. |
Cellular Location | Cell membrane; Single-pass type I membrane protein |
Tissue Location | Widely expressed.. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
LRIG1 act as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation.
References
Rose, J. Phd, et al. Mol. Med. (2010) In press :
Ye, F., et al. J. Neurooncol. 94(2):183-194(2009)
Ljuslinder, I., et al. Breast Cancer Res. 11 (3), 403 (2009) :
Miller, J.K., et al. Cancer Res. 68(20):8286-8294(2008)
Stutz, M.A., et al. Oncogene 27(43):5741-5752(2008)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.